KALVISTA PHARMACEUTICALS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
KALVISTA PHARMACEUTICALS INC. - More news...
KALVISTA PHARMACEUTICALS INC. - More news...
- KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting
- KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
- KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
- KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KalVista Pharmaceuticals, Inc. - KALV
- KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema
- KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop
- KalVista Pharmaceuticals Reports First Fiscal Quarter Results
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference
- KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program
- KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
- KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference
- KalVista Pharmaceuticals Announces Changes to Board of Directors
- KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900
- KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy
- KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
- KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial
